In Deal With BI, Lilly Gets Late-Stage Diabetes Drugs

Eli Lilly & Co., on the precipice of one of the steepest patent cliffs in the industry, announced a diabetes collaboration with Boehringer Ingehheim GmbH Jan. 11 that will recharge the company's diabetes pipeline but may leave investors longing for bigger M&A action.